Navigation Links
George W. Sledge, Jr., M.D., honored for international contributions to breast cancer research
Date:12/6/2010

SAN ANTONIO George W. Sledge Jr., M.D., a nationally recognized pioneer in the development of novel therapies for breast cancer, will receive the 2010 William L. McGuire Memorial Lecture Award at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

Supported by GlaxoSmithKline Oncology (GSK) since its inception in 1992, this honor acknowledges distinguished internationally recognized researchers for their significant contributions to breast cancer research.

Sledge is the Ballve-Lantero Professor of Oncology and professor of medicine and pathology at the Indiana University School of Medicine, and a physician/ researcher at the Indiana University Melvin and Bren Simon Cancer Center. He is also co-director of the the IU Simon Cancer Center's breast program. Sledge specializes in the study and treatment of breast cancer, and his research specifically focuses on molecular and tumor biology, growth factors and anti-angiogenic therapy. He has chaired several nationwide clinical trials involving new therapies for breast cancer.

"Dr. Sledge's work developing novel therapies to treat women with breast cancer has improved the lives of countless cancer patients," said C. Kent Osborne, M.D., codirector of the San Antonio Breast Cancer Symposium and director of the Baylor College of Medicine Dan L. Duncan Cancer Center. "The selection of Dr. Sledge is even more appropriate since he was one of the first medical oncology fellows to graduate the new fellowship training program at the University of Texas Health Science Center Division of Medical Oncology, established by Dr. McGuire as division director in the late 1970s. We congratulate Dr. Sledge on this fitting honor."

Sledge will give a lecture entitled, "What Would Bill Do? Channeling Your Inner McGuire," on Saturday, Dec. 11, 2010, at 11:15 a.m. CT, during the 33rd Annual San Antonio Breast Cancer Symposium. This symposium, encompassing the full spectrum of breast cancer research, will be held Dec. 8-12, 2010, at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

Paolo Paoletti, M.D., senior vice president and head of the oncology R&D unit at GlaxoSmithKline, said "Dr. Sledge has been a true visionary and pioneer in the progression of pathway-related treatments for breast cancer and other diseases. His work with HER2-positive, anti-angiogenesis treatment helped herald a new era in the treatment of breast cancer, and millions of patients have benefitted from this advancement in science. Admirably, all of Dr. Sledge's contributions to research were done with a unique attention and commitment for patients' feelings and needs, which drive everything he does. This award is befitting of such a tremendous scientist and supporter of patient care."

Sledge joined the Indiana University School of Medicine faculty in 1983, after completing his residency at St. Louis University and his fellowship at the University of Texas, San Antonio. He received his undergraduate degree from the University of Wisconsin and his medical degree from Tulane University.

He holds many honors including the Jill Rose Award Breast Cancer Research Foundation (2007) and the 2006 Komen Foundation Brinker Award for Scientific Distinction. Sledge has been listed among "America's Top Doctors" as well as "America's Top Doctors for Cancer."

Sledge is the current president of ASCO and has been an active member of the AACR since 1988. He has served as a breast cancer committee leader with the Hoosier Oncology Group. He serves as chair of the Eastern Cooperative Oncology Group and in various capacities for The Breast Cancer Intergroup. He was secretary (1997-1998) and a board of trustees member (1995-1998) of the Indiana Medical Oncology Society. Sledge has published extensively in the area of breast cancer research, and has served as editor-in-chief of Clinical Breast Cancer.


'/>"/>

Contact: Michele Sharp
michele.sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Georgetown Universitys Howard J. Federoff, M.D., Ph.D. receives Bernard Sanberg Memorial Award
2. George M. Whitesides receives inaugural Dreyfus prize in the chemical sciences
3. American Society for Microbiology honors George Liu
4. Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic
5. George Whitesides accepts inaugural Dreyfus Prize in the Chemical Sciences
6. George Daley to discuss challenges and opportunities facing stem cell scientists
7. Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB
8. Little is understood about alcohols effect on fetal development, Georgetown researchers say
9. Chip Supply Hosts Visit by U.S. Senator George LeMieux
10. George Pólya Prize awarded to Emmanuel Candès and Terence Tao
11. Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
Breaking Biology Technology: